Last reviewed · How we verify
Vinflunine, Carboplatin
At a glance
| Generic name | Vinflunine, Carboplatin |
|---|---|
| Also known as | JAVLOR, CBDCA |
| Sponsor | Pierre Fabre Medicament |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function (PHASE2)
- Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer (PHASE3)
- JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vinflunine, Carboplatin CI brief — competitive landscape report
- Vinflunine, Carboplatin updates RSS · CI watch RSS
- Pierre Fabre Medicament portfolio CI